What is the impact of MRD on the management of patients with 𝐹𝐿𝑇3-mutated AML

During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub was pleased to speak with Alexander Perl, University of Pennsylvania, Philadelphia, US. We asked, What is the impact of MRD on the management of patients with FLT3-mutated acute myeloid leukemia?

Perl discusses the phase III QuANTUM-First trial (NCT02668653) evaluating the impact of FLT3-internal tandem duplication (ITD) measurable residual disease (MRD) positivity as measured by a highly sensitive polymerase chain reaction-next-generation sequencing assay on long-term survival outcomes, and how quizartinib affects MRD levels vs placebo. He then highlights data from the phase III MORHO trial (NCT02997202) assessing the impact of FLT3-ITD MRD status before allogeneic hematopoietic stem cell transplant on posttransplant survival outcomes. Perl concludes by considering the potential integration of FLT3-ITD MRD measurement into routine clinical practice for risk stratification and to guide treatment options.